Patrick T. Lewis

Array ( [id] => 15915309 [patent_doc_number] => 10654883 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Inorganic salts of nicotinic acid mononucleotide as anti-aging agents [patent_app_type] => utility [patent_app_number] => 16/374461 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 12087 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16374461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312819 [patent_doc_number] => 20210401867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => PHOTOSENSITIZERS AND METHOD OF TREATING CANCER USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/612414 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695465 [patent_doc_number] => 10946034 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Methods for the use of 5'-adenosine diphosphate ribose (ADPR) [patent_app_type] => utility [patent_app_number] => 16/364760 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 12 [patent_no_of_words] => 19838 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743751 [patent_doc_number] => 20190255049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION [patent_app_type] => utility [patent_app_number] => 16/361810 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16361810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15753663 [patent_doc_number] => 10618927 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-04-14 [patent_title] => Compositions and methods for modulation of nicotinamide adenine dinucleotide [patent_app_type] => utility [patent_app_number] => 16/362130 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8042 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929849 [patent_doc_number] => 20190300562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/356384 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929847 [patent_doc_number] => 20190300561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/356198 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19180221 [patent_doc_number] => 11986797 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => Superabsorbent polymer and methods of making and using the same [patent_app_type] => utility [patent_app_number] => 16/979836 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10498 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16648734 [patent_doc_number] => 10925888 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Administration of nicotinamide mononucleotide in the treatment of disease [patent_app_type] => utility [patent_app_number] => 16/290122 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 94 [patent_figures_cnt] => 178 [patent_no_of_words] => 34555 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16290122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681219 [patent_doc_number] => 20200095273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/287387 [patent_app_country] => US [patent_app_date] => 2019-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16287387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16548541 [patent_doc_number] => 10881679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Application of a phillyrin/phillygeninin composition in preparing a medicine or health care product for alleviating or/and treating viral diseases, and medicine or health care product for treating viral diseases [patent_app_type] => utility [patent_app_number] => 16/281826 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14722 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16281826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14963065 [patent_doc_number] => 20190309010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/273843 [patent_app_country] => US [patent_app_date] => 2019-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37460 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16273843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14684969 [patent_doc_number] => 20190241599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE [patent_app_type] => utility [patent_app_number] => 16/265256 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309563 [patent_doc_number] => 20190144485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => Process for Making Chloro-substituted Nucleoside Phosphoramidate Compounds [patent_app_type] => utility [patent_app_number] => 16/248273 [patent_app_country] => US [patent_app_date] => 2019-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16248273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178775 [patent_doc_number] => 20190359979 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => OLIGOMERIC COMPOUNDS COMPRISING ALPHA-BETA-CONSTRAINED NUCLEIC ACID [patent_app_type] => utility [patent_app_number] => 16/239781 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178105 [patent_doc_number] => 20190359644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS [patent_app_type] => utility [patent_app_number] => 16/226811 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16226811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17822672 [patent_doc_number] => 11427610 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Cyclic dinucleotides as anticancer agents [patent_app_type] => utility [patent_app_number] => 16/849091 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26647 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 338 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16244780 [patent_doc_number] => 10744104 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-18 [patent_title] => Neprilysin inhibitors [patent_app_type] => utility [patent_app_number] => 16/153299 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46292 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 369 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18747069 [patent_doc_number] => 11806360 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Compositions and methods for treating transthyretin (TTR) mediated amyloidosis [patent_app_type] => utility [patent_app_number] => 16/648558 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 15489 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132325 [patent_doc_number] => 20190100552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/134520 [patent_app_country] => US [patent_app_date] => 2018-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16134520 [rel_patent_id] =>[rel_patent_doc_number] =>)